18th Feb 2020 07:03
Silence Therapeutics to Present at the 2020 Cowen Health Care Conference
18 February 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Dr. Rob Quinn, Chief Financial Officer, will present at the Cowen 40th Annual Health Care Conference in Boston.
Date: | Monday, March 2, 2020 | |
Time: | 4:10 p.m. EST (9:10 p.m. GMT) | |
Location: | Boston Marriott Copley Place, Boston, Mass. |
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
For more information, please contact:
Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray
| Tel: +44 (0) 20 3709 5700 |
U.S. IR Westwicke Peter Vozzo | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit: https://www.silence-therapeutics.com/
Related Shares:
SLN.L